ELTX Stock Overview
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Elicio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.10 |
| 52 Week High | US$24.39 |
| 52 Week Low | US$2.96 |
| Beta | 0 |
| 1 Month Change | 19.74% |
| 3 Month Change | 110.65% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | -1.2% | 2.0% |
| 1Y | n/a | -2.3% | 22.3% |
Return vs Industry: Insufficient data to determine how ELTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ELTX performed against the US Market.
Price Volatility
| ELTX volatility | |
|---|---|
| ELTX Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ELTX's share price has been volatile over the past 3 months.
Volatility Over Time: ELTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 32 | Bob Connelly | elicio.com |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations.
Elicio Therapeutics, Inc. Fundamentals Summary
| ELTX fundamental statistics | |
|---|---|
| Market cap | US$91.89m |
| Earnings (TTM) | -US$35.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs ELTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.20m |
| Earnings | -US$35.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ELTX perform over the long term?
See historical performance and comparison